U.S. markets close in 5 hours 41 minutes

Moleculin Biotech, Inc. (MBRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6101-0.0699 (-1.90%)
As of 10:18AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close3.6800
Open3.6500
Bid3.6200 x 1100
Ask3.6500 x 1000
Day's Range3.5500 - 3.6873
52 Week Range3.1200 - 9.3000
Volume66,866
Avg. Volume1,119,807
Market Cap102.687M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-1.5580
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
    PR Newswire

    Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has commenced enrollment and dosed the first subject in its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.

  • Moleculin Announces Inclusion in the Russell 2000® Index
    PR Newswire

    Moleculin Announces Inclusion in the Russell 2000® Index

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution of the Russell stock indexes, Moleculin has been selected to be added to the Russell 2000® Index effective after the close of the U.S. equity markets on June 25, 2021.

  • Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients
    Benzinga

    Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients

    The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. It has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials to treat acute myeloid leukemia (AML). Phase 1b portion of the trial will determine the maximum-tolerated dose and safety of Annamycin, and Phase 2 will explore the efficacy of Annamycin as a single agent. A maximum of 25 subjects will be enrolled at the RP2D to evaluate efficacy further. The company also expects a second Phase 1b/2 trial of Annamycin in sarcoma lung metastases to be initiated in 2021. Price Action: MBRX shares are up 0.69% at $3.64 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaEyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia StudyBristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.